Intelgenx presentation july 2017

1. 0
TSX-V: IGX
OTCQX: IGXT
WE MAKE APPROVED DRUGS BETTER
Investor Presentation
July 2017
Innovative Drug Delivery Solutions

2. 1
2
To the extent any statements made in this presentation contain information that is not historical, these statements are forward-
looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and
projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-
looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and
other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future
events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to,
risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration and Canadian Therapeutic
Products Directorate approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products
and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished
products, the regulatory environment, tax rate assumptions, the outcome of legal proceedings, fluctuations in operating results
and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission and the
Ontario Securities Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.
2
Forward-Looking Statements

3. 2
2
3
• IntelGenx Corp. Founded
• TSX-V (IGX)1
• OTCQX (IGXT)1
• Market Capitalization
• Shares Issued
• Shares Fully Diluted
• Insider Beneficial Ownership
• Cash/Equivalent
(As of March 31, 2017)
2003
CAD$1.25
US$0.97
CAD$82M
65.5M
70.8M
18.7%
CAD$5.3M*
Analyst Coverage
Firm Analyst
H.C. Wainwright Swayampakula Ramakanth
Singular Research Greg Eisen
Company Snapshot
* As at June 30, 2017
* Does not include proceeds from July 2017 convertible debenture offering

4. 3
Strengthened Management Team
Over 20 Employees, including 7 with Ph.D.’s
Andre Godin, CPA, CA
Executive VP, CFO
• 25+ years biotech/pharma industry
experience
• Member of the Canadian Chartered
Professional Accountants and the
Canadian Institute of Chartered
Accountants
Nadine Paiement, M. Sc.
VP, Research & Development
• Co-inventor of IntelGenx Trilayer
Technology
• 15 years experience in product
development and technology transfer
Stephen Kilmer
Investor Relations
• 20+ years experience in healthcare IR
and PR
• President of Kilmer Lucas, a health-
care only investor relations and capital
markets advisory company
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
• Co-Founder of Listerine breath strips
• 30+ years drug delivery / pharma
experience
• Holds over 40 patents in drug
delivery and numerous scientific
publications
4
Dana Matzen, Ph.D.
VP, Business & Corporate
Development
• 15 years experience in
pharmaceutical product licensing
• Prev. Director, BD at Paladin
• Completed 13 transaction,
7 new product launches
John Durham, B. Sc.
VP, Operations
• 20+ years experience in
pharmaceutical manufacturing, quality
management, product development
• Held executive positions with several
Canadian and US companies

5. 4
We Make Approved Drugs Better
IntelGenx Drug Delivery Technology Platforms
Rapidly disintegrating films improving
drug performance and easing administration
without the need for water
Films
VersaFilm™
Tablets
Controlled-release tablets for oral absorption
over an extended time period
AdVersa™
We Make Approved Drugs Better
5

6. 5
VersaFilmTM Oral Films
Oral Films Provide Significant Market Opportunities
for Improving Drug Delivery
2
• IntelGenx CEO co-developer of the Listerine breath strips
• Oral films ideal for elderly, children, patients who have
difficulty swallowing traditional tablets
• Quicker action to relieve symptoms
VersaFilm™ Oral Films
6

7. 6
7
Advantages of Oral Thin Film Delivery
We are focused on areas where oral films
are particularly well-suited:
Develop and commercialize products that provide therapeutic advantages to patients
leveraging oral films, such as:
• Reduced side effects
• Improved bio-availability
• Response time versus existing drugs
• Abuse resistant
• Convenience
• Lifecycle management
• Repurpose existing drugs for new indications using oral films
• “First-to-file” generic drugs where high technology barriers to
entry exist in reproducing branded films

8. 78
Clearly Defined BD Strategy
Balancing Risks and Opportunities for an Optimized Portfolio
Overall
Risk
Time to MarketSlow Fast
Low
High
Drug Repurposing
Patient Benefits
Lifecycle Mgmt
FTF Generics
IntelGenx Future Focus
Deal Value
Low
Medium
High

9. 8
We Offer Full Service
to Foster the Growth of our Partners
We Offer Full Service
9

10. 9
10
• IntelGenx grants partners exclusive rights to market and sell its products in exchange for
upfront and milestone payments, together with a share of the partner’s net profits or a
royalty on net product sales
• IntelGenx retains manufacturing rights for its products
• Payments are received as the contracted services are performed or when certain
milestones are achieved:
• FDA submission
• FDA approval
• Commercial launch
• Annual net sales target, etc.
• Partners pay for part or all of the R&D expenses associated with developing a new
product and to obtain regulatory approval
Low Risk Development Model

11. 10
11
State-of-the-Art Oral Film Facility Established
For Development & Manufacturing
• 17,000 sq ft facility in Montreal -
construction completed in Q1 2016
• High capacity manufacturing and packaging
equipment
• Lower costs, controls quality
and de-risks investment
for new products
GROSS MARGINS of 40% PLUS

12. 11
For Migraines
Leverages VersaFilm™ Technology
VersaFilm
TM
Rizaport
• European Marketing Approval – November 2015
• Co-development partnership with RedHill Biopharma
− Definitive agreement signed July 2016 with Grupo Juste for Spain
& additional territories
− Definitive agreement signed Dec 2016 with Pharmatronic for
South Korea
− Actively pursuing several opportunities to open new markets
• Patent granted in April 2016 protecting Rizaport
• Re-submission of 505(b)(2) NDA planned for Q4 2017
• PDUFA date expected in early 2018
12

13. 12
For Erectile Dysfunction
VersaFilm
TM
Tadalafil
• A high value, pleasantly flavored, and convenient
VersaFilm™ dosage form of 2.5, 5, 10 and 20 mg
tadalafil that can be administered without water
• Pilot phase 1 clinical trial for safety and
pharmacokinetics have been successively
completed, confirming bioequivalence to Cialis®
(Eli Lilly)
• 2 patents protecting Tadalafil VersaFilm pending
VersaFilm
TM
Tadalafil
13

14. 13
Fr Erectile Dysfunction
• Tadalafil market in the US estimated at $1.7B
• Nov 2017 Lilly’s tadalafil composition patent
to expire, but orange book dosing patent still in
force until April 2020
• IntelGenx’ exclusive license to Lilly’s tadalafil
ED dosing patent ‘166 will allow entry of
Tadalafil VersaFilm™ into the ED US market
upon FDA approval, potentially before the
market entry of Cialis® generic competitors
• 505(b)(2) USA NDA submission in Q3 2017
• Expected US FDA approval H1/2018
$1,703$1,429
$175
$11
$48
$18
US ED Market by Sales ($M)
Cialis
Viagra
Levitra
Staxyn
Stendra
Edex
VersaFilm
TM
Tadalafil Significant Market Opportunity
14

15. 14
For Schizophrenia & Bipolar
1 Disorder
15
• Fast-acting loxapine oral dosage
• For treatment of acute agitation and anxiety
in non-institutionalized patients with
schizophrenia & bipolar 1 disorder
• Reduces risk of pulmonary problems
and potential risk of violence and injury to
patients and others
• US patent & PCT applications submitted
• Formulation optimization stage – results
expected H2 2017
VersaFilm
TM
Loxapine
VersaFilm
TM
Loxapine

16. 15
For Mild Cognitive Impairment
VersaFilm
TM
Montelukast
16
VersaFilm
TM
Montelukast
• IntelGenx is repurposing Montelukast
for the treatment of MCI by leveraging
its VersaFilm™ technology
• The drug is known and approved for a
different indication (asthma) and has an
excellent safety profile
• Strong preclinical evidence
Global Sales for AD by Patients Category
(Global Data, 2013)

17. 16
2
17
Clinical Data
0.0
100.0
200.0
300.0
400.0
500.0
600.0
0.00 5.00 10.00 15.00 20.00 25.00 30.00
Montelukastconcentration(ng/mL)
Time (hrs)
Montelukast Avg Plasma Profile
Test buccal film 10mg
Ref tablet 10mg
VersaFilm
TM
Montelukast
• Phase 1 clinical study in human successfully completed
• Significantly increased bioavailability after administration of VersaFilm™ compared to
commercial tablet
• Drug crosses blood/brain barrier when given as film
• Phase II-a study (proof of concept) to commence Q3/2017
• First efficacy data in humans available Q4/2017
• Several pharma companies have expressed strong interest
Before
MMSE 13:
moderate to severe
dementia
MMSE 22:
mild dementia
After 2 Months of
Montelukast

18. 17
Mucoadhesive Tablet
For Pain Management
• AdVersa® mucoadhesive tablet adheres to the oral
mucosa and releases the drug onto the site of application
at a controlled rate
• Repurposing of synthetic THC dronabinol for use in pain
• Protected by several issued and pending patents
• Competitive advantages vs. Marinol® capsules (Abbvie)
Marinol® (dronabinol) capsule Dronabinol AdVersa®
Conventional oral dosage form AdVersta® mucoadhesive tablet
High rate of metabolization Limited first-pass metabolism
Limited bioavailability Improved bioavailability
Undesired psycho activity
Reduced gastro-intestinal exposure
and side-effects
Limited shelf life Enhanced product stability
AdVersa
TM
DronabinolDronabinol
Mucoadhesive Tablet
For Pain ManagementAdVersa
TM
DronabinolDronabinol
18

19. 18
19
• High dose version of Wellbutrin XL®
• Only approved, once-daily, bupropion HCl 450mg dose in a
single tablet
• Launched commercially October 2013 in partnership with
Edgemont Pharmaceuticals
• Sold US revenue to SWK Holdings for US$6M
• Development cost $2.5M, total revenue $15M = 6-fold ROI
• Non-dilutive source of funding, will be used to advance film
projects
Successful Monetization of First
In-House Development

20. 19
20
• Licensing and development agreements entered for four generic
products
• IntelGenx granted Chemo exclusive worldwide license to
commercialize two generic tablets and U.S. license for two other
generic oral films
• IntelGenx to receive upfront, milestone, R&D revenues and share of
profits – total value of 7 digits
• Combined total market of four products is over $7B
• Chemo making a strategic move into novel drug delivery products
with IntelGenx as its partner
• Partnership could result in numerous future product agreements
About Chemo Group:
• Founded in 1978
• 5,000 employees
• Head office in Spain
• Revenues of $1.2B annually
• Markets over 300 products
• Operating in over 40 countries
• 20 state-of-the-art facilities
• 9 specialized R&D centers
Strategic Partnership with Chemo Group

21. 20
Robust Product Pipeline
Addressing Significant Market Opportunities
21
Migraine – Rizaport®
(Rizatriptan)
Available
ex-ES & SKR
Erectile Dysfunction
(Tadalafil) Available
Schizophrenia
(Loxapine) Available
Neurodegenerative Brain Diseases
(Montelukast) Available
Opioid Dependence - gSuboxone®
(Buprenorphine/ Naloxone)
Partnered
Undisclosed
Partnered
Undisclosed
Partnered
Undisclosed
Partnered
Major Depressive Disorder - Forfivo
XL®
(Bupropion)
Available
ex-US
Hypertension
(undisclosed)
Partnered
Pain
(undisclosed)
Partnered
Pain
(Dronabinol)
Available
ex-US/ CAN
VersaFilmTMTablets

22. 21
22
The IntelGenx Advantage
1. History
• Dr. Zerbe a pioneer with over 30 plus years in oral films
2. Formulation Team
• Strong in applying biopharmaceutical aspects to formulation development
• Top quality scientists: highly creative, focused on problem solving & innovative approaches
• Experienced in developing films for oral (GI), sublingual & buccal absorption
3. Clearly Defined Corporate Strategy And Business Model
• Focus on drug repurposing, lifecycle management, patient benefits, and FTF
• Provider of comprehensive pharmaceutical services to industry partners
4. Competitive Manufacturing Capabilities
• First in Canada
• New state-of-the-art manufacturing facility
• Offer one-stop-shopping to our partners with lean operations keeping costs down
• Customized manufacturing equipment

23. 22
Financial Results
23

24. 23
Financial Performance: Revenue
$M
1.4
0.8
5.2 5.1
0
1
2
3
4
5
6
First Quarter 2017 First Quarter 2016 2016 Full Year 2015 Full Year
Revenue
REVENUE ($M)
23
24

25. 24
Net Comprehensive Income & Adjusted EBITDA ($M)
$M
Financial Performance: Income & EBITDA
25
-0.5
-0.7
-1.5
0.8
-0.1
-0.6
-0.3
1.7
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
First Quarter 2017 First Quarter 2016 2016 Full Year 2015 Full Year
Net Income Adjusted EBITDA

26. 25
Conclusion
26

27. 26
27
Solid Platform for Growth
Significant Market Potential
• New manufacturing facility will offer many competitive advantages
• Strengthened management team to accelerate execution of business plan
• Implemented product sourcing strategy to identify high-value product opportunities
• Building strategic partnerships with relevant partners in the pharmaceutical industry
Solid Platform for Growth

28. 27
28
Thank You!
www.IntelGenx.com
Contact Info:
Stephen Kilmer André Godin
Investor Relations Executive VP & CFO
+1-514-331-7440 ext. 232 +1-514-331-7440 ext. 203
Stephen@intelgenx.com Andre@intelgenx.com
IntelGenx Corporate Offices
6420 Abrams
Saint-Laurent (Quebec)
H4S 1Y2 Canada
www.intelgenx.com